Eclipse Bio
San Diego, US · Founded 2017 · Delaware corporation · 42 employees on LinkedIn · 4 known investors
Eclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.
Founders & leadership
Eclipse Bio was founded in 2017 by Eugene Yeo.
Board

Investors · 4
Reported raises · per SEC filings
Form D private placements$16.9M disclosed across 2 rounds · 2021–2025
▶$4.9MraisedNov 2025 · 7 investors · BiotechnologyRule 506(b)
- Peter ChuExecutive Officer, Director
- Daniel VasellaDirector
- Edmond WongDirector
- Eugene YeoDirector
- Offering amount
- $7.2M
- Amount sold
- $4.9M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedSep 2021 · 10 investors · BiotechnologyRule 506(b)
- Daniel VasellaDirector
- Peter ChuExecutive Officer, Director
- Eric L Van NostrandDirector
- Hallie KuhnDirector
- Eugene W YeoDirector
- Offering amount
- $15M
- Amount sold
- $12M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapCompanies competing with Eclipse Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $349.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.6M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Eclipse Bio do?
- Eclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.
- Who founded Eclipse Bio?
- Eclipse Bio was founded by Eugene Yeo in 2017.
- Who are Eclipse Bio's investors?
- Eclipse Bio's investors include Brainstorm Ventures, iGlobe Partners, Magnetic Ventures, Phoenix Venture Partners.
- How much funding has Eclipse Bio raised?
- Eclipse Bio has disclosed $16.9M raised across 2 rounds.
- Where is Eclipse Bio headquartered?
- Eclipse Bio is headquartered in San Diego, US.

